Key Insights

Highlights

Success Rate

100% trial completion (above average)

Published Results

11 trials with published results (38%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

0.0%

0 terminated out of 29 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

3%

1 trials in Phase 3/4

Results Transparency

46%

11 of 24 completed with results

Key Signals

11 with results100% success

Data Visualizations

Phase Distribution

25Total
Not Applicable (8)
P 1 (11)
P 2 (5)
P 4 (1)

Trial Status

Completed24
Recruiting3
Withdrawn2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 24 completed trials

Clinical Trials (29)

Showing 20 of 20 trials
NCT02272049Phase 1RecruitingPrimary

Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults

NCT02316379Phase 1RecruitingPrimary

Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration

NCT06879639Not ApplicableCompleted

Exercise Impact in Elderly With Multimorbidity: HbA1c and Blood Pressure

NCT06951633Not ApplicableRecruiting

Effects of Pulmonary Rehabilitation in Salt Chambers on Functional Efficiency, Respiratory Parameters, and Blood Rheology in Elderly With Respiratory Diseases.

NCT03894969Phase 2CompletedPrimary

Study to Assess the Immunogenicity and Safety of GSK's Investigational Vaccine (GSK3277511A) When Given to Healthy Smokers and Ex-smokers After Administration of Shingrix Vaccine

NCT03443427Phase 2CompletedPrimary

A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine

NCT03151395Not ApplicableCompletedPrimary

Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease, in Asia Pacific

NCT03201211Phase 1CompletedPrimary

A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults

NCT03281876Phase 2CompletedPrimary

A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.

NCT03557645Not ApplicableCompleted

Ventilator Hyperinflation and Hemodynamics

NCT01587807Phase 1CompletedPrimary

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inhaled GSK1995057

NCT01360398Not ApplicableCompletedPrimary

Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly

NCT01505556Withdrawn

Proprioceptive Postural Control and Diaphragm Paresis

NCT02547974Phase 1CompletedPrimary

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.

NCT02075541Phase 2CompletedPrimary

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.

NCT01476046Phase 1CompletedPrimary

Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects.

NCT01516437Not ApplicableCompletedPrimary

A Study to Assess Immunity to Specific Microbial Antigens in Healthy Smokers and Non-smokers and in Subjects With Stable COPD

NCT01395849CompletedPrimary

Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)

NCT01657526Phase 1CompletedPrimary

Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine

NCT01818024Phase 1CompletedPrimary

A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers

Scroll to load more

Research Network

Activity Timeline